NeoDynamics received FDA clearance for pulse biopsy system NeoNavia®
Stockholm, Sweden September 8, 2022 - The MedTech company NeoDynamics has today received approval for its innovative pulse biopsy system NeoNavia® from the US Food and Drug Administration, FDA. The US breast biopsy market is estimated to reach $830 million by 2025. “The FDA approval for NeoNavia is a major milestone for NeoDynamics and a stamp of quality for both the product and NeoDynamics as a whole,” said Anna Eriksrud, CEO of NeoDynamics. “The US represents the potentially largest market for the product, where we now also can build on the experience gained with the system in